Activity of iclaprim against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae

被引：9
|
作者：
Morrissey, I. [1 ]
Maher, K. [1 ]
Hawser, S. [2 ]
机构：
[1] Quotient Biores Ltd, Microbiol, Fordham CB7 5WW, England
[2] Arpida AG, CH-4153 Reinach, Switzerland
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2009年 / 63卷 / 02期
关键词：
INFECTIONS; RESISTANCE; EUROPE;
D O I：
10.1093/jac/dkn505
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：413 / 414
页数：2
相关论文
共 50 条
  • [1] In Vitro Activity of Iclaprim against Respiratory and Bacteremic Isolates of Streptococcus pneumoniae
    Zhanel, George G.
    Karlowsky, James A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (04) : 1690 - 1692
  • [2] Synergistic antibiotic activity against planktonic and biofilm-embedded Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus oralis
    Moreno, Mercedes Gonzalez
    Trampuz, Andrej
    Di Luca, Mariagrazia
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (11) : 3085 - 3092
  • [3] Activity of Daptomycin Against Multiresistant Clinical Isolates of Staphylococcus aureus and Streptococcus agalactiae
    Sorlozano, Antonio
    Gutierrez, Jose
    Roman, Juan
    Liebana, Jose
    Piedrola, Gonzalo
    MICROBIAL DRUG RESISTANCE, 2009, 15 (02) : 125 - 127
  • [4] In vitro antimicrobial activity of benzalkonium chloride against clinical isolates of Streptococcus agalactiae
    Mosca, A
    Russo, F
    Miragliotta, G
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (03) : 566 - 568
  • [5] A comparison of the activity of tigecycline against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiae
    Sorlozanoa, Antonio
    Gutierrez, Jose
    Roman, Eva
    Luna, Juan de Dios
    Roman, Juan
    Liebana, Jose
    Piedrola, Gonzalo
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 58 (04) : 487 - 489
  • [6] In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities
    Ioannidou, S
    Tassios, PT
    Zachariadou, L
    Salem, Z
    Kanelopoulou, M
    Kanavaki, S
    Chronopoulou, G
    Petropoulou, N
    Foustoukou, M
    Pangalis, A
    Trikka-Graphakos, E
    Papafraggas, E
    Vatopoulos, AC
    CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (07) : 704 - 707
  • [7] Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes
    Al-Lahham, A
    De Souza, NJ
    Patel, M
    Reinert, RR
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (06) : 1130 - 1133
  • [8] PREVALENCE OF IGA RECEPTORS IN CLINICAL ISOLATES OF STREPTOCOCCUS-PYOGENES AND STREPTOCOCCUS-AGALACTIAE - SEROLOGIC DISTINCTION BETWEEN THE RECEPTORS BY BLOCKING ANTIBODIES
    SCHALEN, C
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1993, 7 (01): : 39 - 45
  • [9] A novel bioengineered derivative of nisin displays enhanced antimicrobial activity against clinical Streptococcus agalactiae isolates
    Hayes, K.
    Field, D.
    Hill, C.
    O'Halloran, F.
    Cotter, L.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2019, 19 : 14 - 21
  • [10] Antibiotic Susceptibilities and Serotyping of Clinical Streptococcus Agalactiae Isolates
    Atalay, Altay
    Olcu, Mehmet
    Percin, Duygu
    BALKAN MEDICAL JOURNAL, 2011, 28 (04) : 362 - 365
12345